Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OXB 202

Next Previous
Drug Profile

OXB 202

Alternative Names: EncorStat; OXB-202

Latest Information Update: 28 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oxford BioMedica
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Angiogenesis inhibitors; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Keratoplasty rejection

Most Recent Events

  • 28 Mar 2022 No recent reports of development identified for preclinical development in Keratoplasty-rejection(Prevention) in United Kingdom (Intraocular, Implant)
  • 23 Mar 2020 OXB 202 is still in preclinical development for the treatment of Keratoplasty rejection (Prevention) in United Kingdom (Oxford BioMedica pipeline, March 2020)
  • 23 Aug 2018 OXB 202 is available for licensing as of 23 Aug 2018. http://www.oxfordbiomedica.co.uk/pipeline
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top